Sex: M
Vaccine: COVID19
Symptoms: Magnetic resonance imaging, Myelitis transverse
Clinical narrative: Diagnosed with transverse myelitis a rare condition that involves demyelinated lesion of my thoracic spinal cord; This spontaneous case was reported by a physician and describes the occurrence of MYELITIS TRANSVERSE (Diagnosed with transverse myelitis a rare condition that involves demyelinated lesion of my thoracic spinal cord) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In January 2021, the patient experienced MYELITIS TRANSVERSE (Diagnosed with transverse myelitis a rare condition that involves demyelinated lesion of my thoracic spinal cord) (seriousness criteria disability and medically significant). At the time of the report, MYELITIS TRANSVERSE (Diagnosed with transverse myelitis a rare condition that involves demyelinated lesion of my thoracic spinal cord) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Magnetic resonance imaging: I obtained an MRI in my cervical spine it revealed no acute changes..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were reported.  Lab data included MRI's of thoracic and lumbar spine.  No treatment medication were reported.  dysstasia, asthenia, hypoasesthesia, paraesthesia, fall, gait disturbance, feeling abnormal and electric shock sensation were subsumed under MYELITIS TRANSVERSE.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company comment: This is a spontaneous case regarding a male orthopedic surgeon of unknown age, with no reported medical history, who received first dose of mRNA-1273 vaccine on 30-Dec-2020 and was diagnosed with medically significant and disability event of myelitis transverse in January 2021. He stated that approximately one week after vaccination, he experienced feet numbness, a sensation of pins and needles and electrical shock sensations down the spine radiated to his feet. A cervical spine MRI revealed no acute changes. Days later he fell when he tried to stand from a sitting position, on that same day a thoracic and lumbar spine MRI was performed but results were not provided. He soon saw a neurologist who diagnosed him with transverse myelitis. He has been off work since, he stated that his career is likely over, he could barely walk .The electrical sensations have decreased but the numbness, weakness and poor balance persisted. No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case regarding a male orthopedic surgeon of unknown age, with no reported medical history, who received first dose of mRNA-1273 vaccine on 30-Dec-2020 and was diagnosed with medically significant and disability event of myelitis transverse in January 2021. He stated that approximately one week after vaccination, he experienced feet numbness, a sensation of pins and needles and electrical shock sensations down the spine radiated to his feet. A cervical spine MRI revealed no acute changes. Days later he fell when he tried to stand from a sitting position, on that same day a thoracic and lumbar spine MRI was performed but results were not provided. He soon saw a neurologist who diagnosed him with transverse myelitis. He has been off work since, he stated that his career is likely over, he could barely walk .The electrical sensations have decreased but the numbness, weakness and poor balance persisted. No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.